Sutro Biopharma (STRO) Current Leases (2021 - 2025)

Sutro Biopharma (STRO) has 5 years of Current Leases data on file, last reported at $7.8 million in Q4 2025.

• For the quarter ending Q4 2025, Current Leases rose 4.05% year-over-year to $7.8 million; the trailing twelve-month figure through Dec 2025 stood at $7.8 million (up 4.05% YoY), and the FY2025 full-year result was $7.8 million, up 4.05% from the prior year.
• Current Leases retreated to $7.8 million in Q4 2025, from $8.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $8.1 million in Q2 2025 to a low of $1.0 million in Q4 2021.
• A 5-year average of $5.3 million and a median of $6.3 million in 2023 frame the typical range for Current Leases.
• Across the five-year window, Current Leases surged 429.82% in 2023 and increased 4.05% in 2025, its largest moves.
• Tracing STRO's Current Leases over 5 years: stood at $1.0 million in 2021, then jumped by 342.14% to $4.6 million in 2022, then jumped by 40.02% to $6.4 million in 2023, then advanced by 16.51% to $7.5 million in 2024, then gained by 4.05% to $7.8 million in 2025.
• Business Quant data shows STRO's Current Leases at $7.8 million in Q4 2025, $8.0 million in Q3 2025, and $8.1 million in Q2 2025.